-
ComboMATCH Screening Trial Opens New Doors for Precision Cancer Treatment
A nationwide screening trial called ComboMATCH is using genetic testing to connect patients with advanced solid tumors to targeted therapy combinations that may better match their tumor’s unique biology.
-
Asahi Kasei Advances Novel Peptide Candidate Into Phase I Trial for Autoimmune Diseases
Asahi Kasei has begun a Phase I clinical trial for a new peptide candidate aimed at treating autoimmune diseases, marking an early but promising step toward potential new therapeutic options.
-
Lilly’s Retatrutide Hits Major Milestone: Phase 3 Trial Shows Significant Weight Loss and Osteoarthritis Pain Relief
Eli Lilly’s triple agonist retatrutide succeeded in its first Phase 3 trial, delivering substantial average weight loss alongside meaningful relief from osteoarthritis-related joint pain in participants.
-
New Clinical Trial Explores Optimal Timing for Vasopressin in Septic Shock Care
A new pilot study, CASPER-Pilot, is testing innovative clinical decision support technology to help doctors determine the ideal timing for administering the peptide hormone vasopressin in septic shock patients.
-
New Clinical Trial Aims to Identify the Best Treatment for a Rare Autoimmune Disease
A new 160-patient trial will directly compare five FDA-approved therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD), aiming to give patients and doctors clearer guidance on the most effective, safest treatment options.
-
New Clinical Trial Explores Bevacizumab to Reduce Surgeries for Recurrent Respiratory Papillomatosis
A new clinical trial is investigating whether the drug bevacizumab can help reduce the number of surgeries needed by adults living with recurrent respiratory papillomatosis (RRP), a rare condition causing airway growths.
-
FDA Signals Support for Peptides Following Extensive Review
After a thorough deliberation process, the FDA has voted in favor of peptides, a decision that could preserve or expand access to these compounds for patients and practitioners. The outcome reflects careful regulatory consideration of the science behind peptide therapies.
-
Personalized Neoantigen DNA Vaccine Shows Promise in Early Glioblastoma Trial
A Phase 1 trial published in Nature reports that a personalized, multivalent neoantigen DNA vaccine was safe and generated immune activity in patients with a hard-to-treat form of glioblastoma.
-
Understanding Peptides: How They’re Shaping Medicine, Skincare, and Wellness
Peptides continue to expand into everyday health and wellness, from FDA-approved medical treatments to skincare formulations, reflecting their growing versatility as a class of compounds.
-
FDA Approves Rusfertide (MIMRYLO™), a Hepcidin-Mimetic Peptide, for Polycythemia Vera
Protagonist Therapeutics has received U.S. FDA approval for MIMRYLO™ (rusfertide), a novel hepcidin mimetic peptide designed to help manage polycythemia vera. The approval marks a new peptide-based treatment option for patients with this rare blood disorder.